Check these out on the iPad edition of this issue by OT reporters Sarah Maxwell and Peter Goodwin:
Esophageal Cancer: Fewer Postop Complications with Hybrid Minimally Invasive Esophagectomy
PODCAST: Christophe Mariette, MD, PhD, a surgeon at University Hospital of Lille in France, discusses the multicenter, randomized, controlled Phase III MIRO trial, which showed that patients with resectable esophageal cancers who had minimally invasive surgery had similar outcomes but fewer postoperative problems compared with patients receiving standard esophagectomy (Abstract 5). Adding his perspective is the Chair of the Session, Michael Kent, MD, Director of Minimally invasive Thoracic Surgery at Beth Israel Deaconess Medical Center in Boston.
Genomic Profiling of Biliary Tract Cancers to Optimize Outcomes
PODCAST: Jeffrey S. Ross, MD, the Cyrus Strong Merrill Professor and Chair of the Department of Pathology and Laboratory Medicine at Albany Medical College in New York and Medical Director of Foundation Medicine in Cambridge, Massachusetts, discusses how such genomic profiling in this group of patients revealed tumor-specific differences and genomic alterations that could serve as therapeutic targets for individualizing cancer therapy (Abstract 231).
Anti-PD-1 Antibody in Advanced Gastric Cancer: Good Results with Manageable Toxicity
VIDEO: Kei Muro, MD, from Aichi Cancer Center Hospital in Japan, reviews the KEYNOTE-012 study showing that harnessing PD-L1 expression with pembrolizumab in patients with advanced gastric cancer was effective and had tolerable toxicity (Abstract 3). He and his colleagues concluded that the results support the ongoing development of pembrolizumab for gastric cancer.
If you are not yet receiving our iPad issues, download the free Oncology Times app from the App Store today! Visithttp://bit.ly/OT-iPadApp, search in the App Store, or follow the link onhttp://oncology-times.com.